Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan- for Dapagliflozin in Management of Type 2 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REWARD
- Sponsors AstraZeneca
- 15 Mar 2018 Planned End Date changed from 28 Feb 2018 to 15 Jun 2018.
- 15 Mar 2018 Planned primary completion date changed from 28 Feb 2018 to 15 Jun 2018.
- 10 Jun 2017 Biomarkers information updated